HELP – cybin inc. (US:NASDAQ)
Stock Stats
News
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Helus Pharma appoints Michael Cola as CEO [Seeking Alpha]
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Cybin (NASDAQ:HELP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $22.00 price target on the stock.
Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq [Yahoo! Finance]
Form 6-K CYBIN INC. For: Feb 10
Form D CYBIN INC.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.